# Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

> **NCT01780545** · PHASE2 · COMPLETED · sponsor: **Noah Hahn, M.D.** · enrollment: 200 (actual)

## Conditions studied

- Bladder Cancer
- Urothelial Carcinoma

## Interventions

- **DRUG:** OGX-427
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01780545
- **Lead sponsor:** Noah Hahn, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-07-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01780545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01780545, "Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01780545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*